BPN14770

DRUG10 trials

Sponsors

Tetra Discovery Partners, National Institute of Mental Health (NIMH), Shionogi

Conditions

Alzheimer DiseaseAlzheimer's DiseaseDepressionFXSFra(X) SyndromeFragile X SyndromeHealthy ParticipantsHepatic Impairment

Phase 1

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

CompletedNCT02648672

Tetra Discovery PartnersAlzheimer's Disease

Start: 2015-12-31End: 2016-07-31Updated: 2017-01-18

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

CompletedNCT02840279

Tetra Discovery PartnersAlzheimer's Disease

Start: 2016-06-30End: 2016-12-31Updated: 2017-01-18

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

CompletedNCT03030105

Tetra Discovery PartnersAlzheimer Disease

Start: 2017-01-31End: 2017-06-30Updated: 2018-10-16

Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)

CompletedNCT03861000

National Institute of Mental Health (NIMH)Depression

Start: 2019-03-12End: 2020-02-11Updated: 2021-03-22

A Study to Assess the Effects of BPN14770 on Rosuvastatin

CompletedNCT07011992

ShionogiHealthy Participants

Start: 2025-07-18End: 2025-08-07Updated: 2025-08-14

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

CompletedNCT07012005

ShionogiRenal Impairment

Start: 2025-08-25End: 2025-12-15Updated: 2026-02-27

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

CompletedNCT07018492

ShionogiHepatic Impairment

Start: 2025-08-30End: 2025-11-26Updated: 2026-02-27

Phase 2

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

CompletedNCT03569631

Tetra Discovery PartnersFragile X Syndrome, Fra(X) Syndrome, FXS

Start: 2018-07-09End: 2020-07-31Updated: 2024-12-19

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

CompletedNCT03817684

Tetra Discovery PartnersAlzheimer's Disease

Start: 2019-04-30End: 2020-02-04Updated: 2025-02-18

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

Active, not recruitingNCT06717438

ShionogiJordan's Syndrome, PPP2R5D Neurodevelopmental Disorder

Start: 2025-05-13End: 2027-12-31Updated: 2026-06-09

Related Papers

A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes

Nature Communications2022-08-3026 citations

Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.

2021-04-2998 citations

The Use of Facebook Advertising to Recruit Healthy Elderly People for a Clinical Trial: Baseline Metrics

JMIR Research Protocols2018-01-2457 citations